EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy

Pascal Reynier iD, Mathieu Michel iD, Patrick Vandeputte iD, Noemi Albano iD, Dario Zoppi iD, Charlène Gillet, Sara Pini iD, Andi Nuredini iD, Martina De Maria iD, Odile Blanchet iD, Naig Gueguen iD, Juan Manuel Chao de la Barca iD und 3 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2026-12 · 17 (6)

DOI: 10.1002/jcsm.70414 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 06.11.2026. Verfasst von Pascal Reynier und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France. Hauptthemen laut MEDLINE: Muscular Dystrophy, Facioscapulohumeral, Biomarkers, Metabolomics, Metabolome. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amis FSH, Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is one of the most common adult‐onset myopathies and is causally associated with a contraction of the D4Z4 macrosatellite repeat array on chromosome 4. It presents with a variable pattern of progressive muscle weakness affecting the face, shoulder girdle and lower limbs. Pathophysiological mechanisms remain incompletely understood, and no effective treatments are available. Moreover, the lack of validated biomarkers limits the assessment of disease progression and therapeutic effects in clinical trials. Metabolic dysfunction has been hypothesized as a contributing factor, yet remains poorly explored.

Methods

In this multicentre, observational, cross‐sectional case–control study, we performed quantitative plasma metabolomics by mass spectrometry in 57 patients (age: 41.8 ± 11.9; females/males ratio: 1.04) with mild to moderate facioscapulohumeral muscular dystrophy (FSHD clinical score 6.4 ± 2.6) and age‐ and sex‐comparable controls (age: 41.1 ± 11.2; females/males ratio: 1.13) recruited from three tertiary neuromuscular reference centres. We restricted inclusion to patients with preserved ambulatory capacity to better capture systemic metabolic alterations not primarily driven by advanced disability. We analysed the data using an integrative framework combining univariate and multivariate analyses with five machine‐learning classifiers.

Results

We identified 57 circulating metabolites discriminating patients from controls, suggesting systemic perturbations in nitric oxide, mitochondrial and one‐carbon metabolism, as well as oxidative stress, muscle mass maintenance and lipid membrane remodelling. Notably, decreased creatinine (fold change in patients vs. controls: 0.754; FDR‐corrected p = 0.000003) and increased asymmetric dimethylarginine (ADMA; fold change in patients vs. controls: 1.168; FDR‐corrected p = 0.000704) emerged as the most significantly altered metabolites, both showing strong correlations with clinical neuromuscular functional scores, including muscle strength (creatinine ρ = 0.62, p = 0.0001; ADMA ρ = 0.34, p = 0.0124), facioscapulohumeral muscular dystrophy severity score (creatinine ρ = 0.53, p = 0.0001; ADMA ρ = 0.32, p = 0.0145) and the daily activity limitation ACTIVLIM scale (creatinine ρ = 0.38, p = 0.0035; ADMA ρ = 0.35, p = 0.008). Plasma levels of GDF15, a biomarker commonly used to support the diagnosis of mitochondrial diseases, were modestly but significantly elevated in patients versus controls (542.3 pg/mL ± 277.2 vs. 444.4 pg/mL ± 164.5, p = 0.043). Further analysis of a predefined mitochondria‐related metabolite panel showed coordinated alterations involving mitochondrial metabolic pathways and discriminated FSHD1 patients from controls (best AUC = 0.83).

Conclusions

These findings highlight systemic metabolic disturbances already detectable in mild‐to‐moderate stages of facioscapulohumeral muscular dystrophy, identifying creatinine and ADMA as promising biomarkers of disease severity, and expand current knowledge of disease pathophysiology. Trial Registration: ClinicalTrials.gov identifier: NCT06086548

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, FacioscapulohumeralBiomarkersMetabolomicsMetabolomeHumansFemaleSeverity of Illness IndexMaleAdultCase-Control StudiesMiddle AgedCross-Sectional Studies

Stichwörter der Autor:innen

ADMAFSHDcreatininemetabolismmetabolomicsmitochondria

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, University Hospital of Angers, Angers, France.
  • Mitovasc Research Unit, CNRS 6015, INSERM U-1083, University of Angers, Angers, France.
  • Neuromuscular Reference Center, Department of Neurology, University Hospital of Angers, Angers, France.
  • Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples "Federico II", Naples, Italy.
  • Biobank of the University Hospital of Angers, Angers, France.

ORCID-Profile: Pascal Reynier, Mathieu Michel, Patrick Vandeputte, Noemi Albano, Dario Zoppi, Sara Pini, Andi Nuredini, Martina De Maria, Odile Blanchet, Naig Gueguen, Juan Manuel Chao de la Barca, Lucia Ruggiero, Rossella Tupler, Marco Spinazzi

Förderung

  • Amis FSH
  • Institut National de la Santé et de la Recherche Médicale

Zitieren

APA

Reynier, P., Michel, M., Vandeputte, P., Albano, N., Zoppi, D., Gillet, C., Pini, S., Nuredini, A., De Maria, M., Blanchet, O., Gueguen, N., Chao de la Barca, J. M., Ruggiero, L., Tupler, R., & Spinazzi, M. (2026). Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy. Journal of Cachexia, Sarcopenia and Muscle, 17(6). https://doi.org/10.1002/jcsm.70414

Vancouver

Reynier P, Michel M, Vandeputte P, Albano N, Zoppi D, Gillet C, et al. Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy. Journal of Cachexia, Sarcopenia and Muscle. 2026;17(6). doi:10.1002/jcsm.70414

BibTeX
@article{Reynier2026,
  author = {Reynier, Pascal and Michel, Mathieu and Vandeputte, Patrick and Albano, Noemi and Zoppi, Dario and Gillet, Charlène and Pini, Sara and Nuredini, Andi and De Maria, Martina and Blanchet, Odile and Gueguen, Naig and Chao de la Barca, Juan Manuel and Ruggiero, Lucia and Tupler, Rossella and Spinazzi, Marco},
  title = {Metabolomics Reveals Multiple Metabolic Alterations and Biomarkers of Disease Severity in Facioscapulohumeral Muscle Dystrophy},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  volume = {17},
  number = {6},
  doi = {10.1002/jcsm.70414}
}
Kostenlos starten →